MetaCap

Aclaris Therapeutics (ACRS) vs Bicara Therapeutics (BCAX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aclaris Therapeutics (ACRS) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 37.1% versus a loss of 53.2%. Bicara Therapeutics is the larger company by market cap ($560.3 million vs $545.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRS+37.05%BCAX-53.22%
+171%+52%-67%
Nov 21, 20251 yearNov 20, 2026
ACRS+191.53%BCAX-63.95%
+469%+190%-89%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRS versus BCAX key metrics
MetricACRSBCAX
Share price$3.44$8.44
Market cap$545.63M$560.31M
1-day change-1.71%-7.46%
YTD return+14.29%-49.85%
1-year return+37.05%-53.22%
5-year return-72.74%—
EPS (TTM)$-0.59$-3.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.83M—
Revenue growth (YoY)-58.19%—
Net income (latest FY)$-64.92M$-137.95M
Gross margin73.28%—
Operating margin-975.91%—
Net margin-829.58%—
52-week high$6.60$30.99
52-week low$2.46$7.87
Distance from 52-week high-47.88%-72.77%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+205.23%+281.16%
Average volume3.07M1.20M
Shares outstanding158.61M66.39M
Employees69103
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACRS has outperformed BCAX by 90.3 percentage points over the past year.

About Aclaris Therapeutics

ACRS stock →

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Bicara Therapeutics

BCAX stock →

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

ACRS vs BCAX FAQ

Which is bigger, Aclaris Therapeutics or Bicara Therapeutics?

Bicara Therapeutics (BCAX) is larger, with a market capitalization of $560.31M compared with $545.63M for Aclaris Therapeutics (ACRS).

Which stock has performed better over the past year, ACRS or BCAX?

ACRS returned +37.05% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.

Are Aclaris Therapeutics and Bicara Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons